Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 8 Carcinoma, Non-Small-Cell Lung 6 Breast Neoplasms 6 Sarcoma 5 Unspecified Adult Solid Tumor, Protocol Specific 4 Neoplasm Metastasis 4 Colorectal Neoplasms 4 Neoplasms 3 Melanoma 3 Colonic Neoplasms 3 Thymoma 2 Rectal Neoplasms 2 Primary Myelofibrosis 2 Pancreatic Neoplasms 2 Myeloproliferative Disorders 2 Multiple Myeloma 2 Mesothelioma, Malignant 2 Leukemia, Myelomonocytic, Chronic 2 Esophageal Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Thrombocytosis 1 Thrombocythemia, Essential 1 Solid Tumor, Adult 1 Small Cell Lung Carcinoma 1 Sarcoma, Synovial 1 Recurrence 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1

Interventions

Temozolomide 41 Radiotherapy 15 Magnetic Resonance Spectroscopy 12 Surgical Procedures, Operative 10 Bevacizumab 10 Irinotecan 9 Radiation 8 Nivolumab 7 Carmustine 7 Specimen Handling 6 Radiosurgery 6 Carboplatin 6 ribociclib 5 O(6)-benzylguanine 5 Imiquimod 5 IL13-PE38 5 Flucytosine 5 Filgrastim 5 Erlotinib Hydrochloride 5 Cyclophosphamide 5 Aminolevulinic Acid 5 vandetanib 4 sargramostim 4 Topotecan 4 Lomustine 4 Imatinib Mesylate 4 Etoposide 4 Craniotomy 4 vocimagene amiretrorepvec 3 temsirolimus 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Glioma × Celecoxib × Clear all

NCT02115074 2026-03-18

FLUVABREX

Centre Oscar Lambret

Phase 1 Completed

Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡